Lista de obras -

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

artículo científico publicado en 2007

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

artículo científico publicado en 2011

A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): a case report

artículo científico publicado en 2008

A retrospective study evaluating the impact of infectious complications during azacitidine treatment

artículo científico publicado en 2017

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

artículo científico publicado en 2017

Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

artículo científico publicado en 2004

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine

artículo científico publicado en 2012

Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.

artículo científico publicado en 2012

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

artículo científico publicado en 2010

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

artículo científico publicado en 2014

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

artículo científico publicado en 2009

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

artículo científico publicado en 2006

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

artículo científico publicado en 2013

Causes of death in 2877 patients with myelodysplastic syndromes

artículo científico publicado en 2016

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes

artículo científico publicado en 2015

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years

artículo científico publicado en 2015

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

artículo científico publicado en 2012

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system

artículo científico publicado en 2011

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data

artículo científico publicado en 2013

Complete remission of a metastatic pancreatic carcinoma after modified G-FLIP therapy

artículo científico publicado en 2007

Correlation between the low marrow blast cutpoint and WHO classification for myelodysplastic syndromes.

artículo científico publicado en 2012

Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective

artículo científico publicado en 2010

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

artículo científico publicado en 2015

Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis

artículo científico publicado en 2017

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance

artículo científico publicado en 2017

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

artículo científico publicado en 2016

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro

artículo científico publicado en 2015

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

artículo científico publicado en 2011

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

artículo científico publicado en 2007

Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia

artículo científico publicado en 2006

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

artículo científico publicado en 2012

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

artículo científico publicado en 2013

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

artículo científico publicado en 2008

Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysis

artículo científico publicado en 2012

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

artículo científico publicado en 2013

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome

artículo científico publicado en 2009

Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).

artículo científico publicado en 2016

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

artículo científico publicado en 2018

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

artículo científico publicado en 2017

Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly

artículo científico publicado en 2008

Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.

artículo científico publicado en 2008

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

article published in 2018

Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes

artículo científico publicado en 2010

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy

artículo científico publicado en 2016

Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer

artículo científico publicado en 2004

Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis

artículo científico publicado en 2014

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group

artículo científico publicado en 2015

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome

artículo científico publicado en 2016

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

artículo científico publicado en 2018

Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics

artículo científico publicado en 2004

Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen

artículo científico publicado en 2003

Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation

artículo científico publicado en 2017

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

artículo científico publicado en 2010

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity

artículo científico publicado en 2016

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

artículo científico publicado en 2011

Impact on survival of different treatments for myelodysplastic syndromes (MDS).

artículo científico publicado en 2009

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes

artículo científico publicado en 2015

In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time

artículo científico publicado en 2015

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry

artículo científico publicado en 2011

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

artículo científico publicado en 2017

Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome ⬇️

artículo científico publicado el 23 de octubre de 2003

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

artículo científico publicado en 2016

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

artículo científico publicado en 2004

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

artículo científico publicado en 2008

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

artículo científico publicado en 2014

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

artículo científico publicado en 2012

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

artículo científico publicado en 2007

Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.

artículo científico publicado en 2008

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

artículo científico publicado en 2009

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

artículo científico publicado en 2011

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

artículo científico publicado en 2017

Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).

artículo científico publicado en 2016

Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.

artículo científico publicado en 2009

Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia

artículo científico publicado en 2009

Mesenchymal stromal cells in myeloid malignancies

artículo científico publicado en 2016

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study

artículo científico publicado en 2013

Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia

artículo científico publicado en 2006

Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.

artículo científico publicado en 2007

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

artículo científico publicado en 2011

Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the fore

artículo científico publicado en 2017

Myelodysplastic syndromes--new treatment options

artículo científico publicado en 2006

Myelodysplastic syndromes. Diagnosis and therapeutic strategies

artículo científico publicado en 2002

Myelodysplastic syndromes: diagnosis, prognosis, and treatment

artículo científico publicado en 2013

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

artículo científico publicado en 2012

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

artículo científico publicado en 2017

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value ⬇️

artículo científico publicado el 6 de agosto de 2010

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts

article

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

artículo científico publicado en 2009

Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling

artículo científico publicado en 2005

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

artículo científico publicado en 2017

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

artículo científico publicado en 2017

Paradigm change in the assessment of myeloid and lymphoid neoplasms associated with occupational benzene exposure

artículo científico publicado en 2009

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

artículo científico publicado en 2012

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

artículo científico publicado en 2017

Perspectives in the prognostication of myelodysplastic syndromes.

artículo científico publicado en 2005

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

artículo científico publicado en 2009

Practice of recognizing benzene-caused occupational diseases in 2006

artículo científico publicado en 2008

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

artículo científico publicado en 2018

Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.

artículo científico publicado en 2004

Prognostic molecular markers in myelodysplastic syndromes ⬇️

artículo científico publicado el 1 de octubre de 2009

Prognostic scoring systems in MDS.

artículo científico

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

artículo científico publicado en 2015

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

artículo científico publicado en 2017

Proposed score for survival of patients with myelodysplastic syndromes

artículo científico publicado en 2013

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes

artículo científico publicado en 2006

Rationale for bone marrow examination in patients with inflammatory rheumatic diseases

artículo científico publicado en 2009

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

artículo científico publicado en 2012

Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow

artículo científico publicado en 2013

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)

artículo científico publicado en 2008

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

artículo científico publicado en 2006

Refractory anemia (RA) and refractory cytopenia with multilineage dysplasia (RCMD) in WHO classification: comparison between Japanese and German cases

artículo científico publicado en 2004

Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals

artículo científico publicado en 2003

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment ⬇️

journal article from 'International Journal of Molecular Sciences' published in 2019

Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning

artículo científico publicado en 2002

Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine

artículo científico publicado en 2009

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

artículo científico publicado en 2014

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2005

Revised international prognostic scoring system for myelodysplastic syndromes

artículo científico publicado en 2012

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

artículo científico publicado en 2010

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma

artículo científico publicado en 2006

Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9

artículo científico publicado en 2016

Secondary acute myeloid leukaemia with monosomy 7 in identical adult twins

artículo científico publicado en 2002

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

artículo científico publicado en 2016

Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease

artículo científico publicado en 2007

Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.

artículo científico publicado en 2016

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

artículo científico publicado en 2009

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group

artículo científico publicado en 2012

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes

artículo científico publicado en 2013

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

artículo científico publicado en 2009

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

artículo científico publicado en 2006

The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany

artículo científico publicado en 2013

The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system

artículo científico publicado en 2014

The sepsis-related Organ Failure Assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation.

artículo científico publicado en 2008

Therapy-related myeloid neoplasms following treatment with radioiodine

artículo científico publicado en 2011

Time-dependent changes in mortality and transformation risk in MDS.

artículo científico publicado en 2016

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Gro

artículo científico publicado en 2014

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study

artículo científico publicado en 2005

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

artículo científico publicado en 2004

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

artículo científico publicado en 2011

Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

artículo científico publicado en 2017

Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation

artículo científico publicado en 2002

Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen

artículo científico publicado en 2011

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts

artículo científico publicado en 2012

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group

artículo científico publicado en 2014

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

artículo científico publicado en 2013

Lista de obras de

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): a case report

A retrospective study evaluating the impact of infectious complications during azacitidine treatment

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine

Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Causes of death in 2877 patients with myelodysplastic syndromes

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data

Complete remission of a metastatic pancreatic carcinoma after modified G-FLIP therapy

Correlation between the low marrow blast cutpoint and WHO classification for myelodysplastic syndromes.

Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysis

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome

Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly

Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy

Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer

Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics

Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen

Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

Impact on survival of different treatments for myelodysplastic syndromes (MDS).

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes

In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome ⬇️

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).

Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.

Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia

Mesenchymal stromal cells in myeloid malignancies

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study

Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia

Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.